Interleukins

Interleukins (ILs) are a large family of cytokines — small signaling proteins that mediate communication between leukocytes (white blood cells) and other cell types. First identified in the 1970s as factors that signal "between leukocytes" (hence the name), interleukins are now known to be produced by and act upon a far broader range of cells, including keratinocytes, fibroblasts, and endothelial cells . Over 40 interleukins have been characterized to date, each playing distinct roles in immune regulation, inflammation, and tissue repair.

Key Interleukins in Skin Biology

Pro-Inflammatory Interleukins

Several interleukins drive the inflammatory response that follows skin injury or irritation :

• IL-1α and IL-1β — The "alarm" cytokines. IL-1α is constitutively stored in keratinocytes and released immediately upon cell damage, acting as a danger signal. IL-1β requires enzymatic processing by caspase-1 and the inflammasome before secretion. Both activate the NF-κB pathway and initiate the inflammatory cascade in skin.
• IL-6 — A pleiotropic interleukin that bridges innate and adaptive immunity. In acute injury, IL-6 drives the acute-phase response and promotes neutrophil recruitment. However, chronically elevated IL-6 sustains low-grade inflammation (inflammaging) and upregulates matrix metalloproteinases (MMPs) that degrade collagen .
• IL-8 (CXCL8) — A potent chemokine that recruits neutrophils to sites of tissue damage. Overproduction of IL-8 leads to excessive neutrophil infiltration and collateral tissue destruction.
• IL-17 — Produced by Th17 cells, IL-17 plays a central role in psoriasis and other inflammatory skin conditions by amplifying keratinocyte activation and neutrophil recruitment.

Anti-Inflammatory Interleukins

Certain interleukins actively suppress inflammation and promote tissue resolution :

• IL-10 — The most potent anti-inflammatory interleukin. IL-10 inhibits the production of TNF-α, IL-1β, IL-6, and IL-8 by macrophages and dendritic cells. It promotes regulatory T-cell differentiation and is essential for preventing excessive tissue damage during immune responses. In wound healing, IL-10 favors scarless or minimal-scar repair.
• IL-4 and IL-13 — Drive macrophage polarization from the pro-inflammatory M1 phenotype to the reparative M2 phenotype, facilitating tissue remodeling and collagen synthesis.
• IL-37 — A relatively recently characterized member of the IL-1 family that suppresses both innate and adaptive immune responses, acting as a natural brake on inflammation.

How PDRN Modulates Interleukins

PDRN exerts its anti-inflammatory effects primarily through activation of the adenosine A2A receptor, which triggers a cAMP-PKA signaling cascade that suppresses NF-κB — the transcription factor responsible for driving production of pro-inflammatory interleukins .

The documented effects of PDRN on interleukin signaling include:

• Suppression of IL-6 — PDRN significantly reduces IL-6 secretion in both wound models and skin rejuvenation contexts, mitigating chronic inflammatory signaling and inflammaging .
• Reduction of IL-1β — By dampening NF-κB activity, PDRN indirectly reduces the transcription and release of IL-1β, blunting the initial inflammatory alarm signal.
• Reduction of IL-8 — Lower IL-8 levels limit excessive neutrophil recruitment, reducing collateral tissue damage at the treatment site.
• Promotion of IL-10 — PDRN shifts the cytokine balance toward anti-inflammatory resolution by upregulating IL-10 expression, which in turn suppresses further pro-inflammatory interleukin production .

This rebalancing of the interleukin environment — suppressing inflammatory interleukins while promoting anti-inflammatory ones — creates conditions favorable for tissue repair rather than tissue destruction.

Clinical Significance

Understanding interleukin modulation explains key clinical benefits of PDRN :

• Post-procedure healing — Reduced IL-6 and IL-8 at treatment sites accelerates recovery after laser treatments, microneedling, and chemical peels by preventing excessive inflammatory infiltration.
• Anti-aging — Suppression of chronically elevated IL-6, a hallmark of inflammaging, protects existing collagen from MMP-mediated degradation while PDRN simultaneously stimulates new collagen production.
• Sensitive skin management — Interleukin imbalance drives chronic skin reactivity; PDRN's ability to restore IL-10/IL-6 balance helps calm persistently reactive skin.
• Scar prevention — Elevated IL-6 and IL-1β during healing promote fibrotic scarring. PDRN's interleukin modulation supports normal tissue architecture over fibrotic repair.

Key Takeaway

Interleukins are the core signaling molecules through which the immune system coordinates skin inflammation and repair. The balance between pro-inflammatory interleukins (IL-1β, IL-6, IL-8) and anti-inflammatory interleukins (IL-10, IL-4) determines healing outcomes. PDRN's A2A receptor-mediated suppression of inflammatory interleukins and promotion of IL-10 is a fundamental mechanism underlying its clinical efficacy in wound healing, skin rejuvenation, and anti-aging therapy .

Related Concepts

• Cytokines — The broader family of signaling proteins that includes interleukins
• Anti-Inflammatory Pathways — The NF-κB and cAMP-PKA cascades that interleukins activate and PDRN modulates
• Wound Healing — The multi-phase repair process governed by interleukin signaling
• Polydeoxyribonucleotide — Full overview of PDRN's mechanism of action